List of Excipients in Branded Drug DIDANOSINE

Generic Drugs Containing DIDANOSINE

Company	Ingredient	NDC	Excipient
State of Florida DOH Central Pharmacy	didanosine	53808-0236	CELLULOSE, MICROCRYSTALLINE
State of Florida DOH Central Pharmacy	didanosine	53808-0236	CROSCARMELLOSE SODIUM
State of Florida DOH Central Pharmacy	didanosine	53808-0236	D&C RED NO. 28

What are the Most Frequently-Used Excipients in DIDANOSINE?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM

Didanosine Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Didanosine is an off-patent nucleoside reverse-transcriptase inhibitor with limited current commercial value as a standalone HIV product. The main formulation opportunity is not a new chemical entity or broad patent-protected product. It is a technically controlled, low-volume formulation for resource-limited markets, pediatric use, veterinary research, clinical supply, or combination regimens. The central excipient issue is didanosine’s acid sensitivity, which historically required alkaline buffering and separation from food or acidic beverages. Any new product would need to improve dose convenience, stability, pediatric acceptability, or supply economics without recreating the manufacturing complexity of legacy buffered formulations.

What is didanosine and how was it regulated?

Didanosine, also known as ddI, is a synthetic purine nucleoside analogue that inhibits HIV reverse transcriptase after intracellular conversion to its active triphosphate. Bristol-Myers Squibb commercialized it as Videx and Videx EC.

The FDA approved didanosine in 1991 for HIV infection. The original product was a buffered chewable or dispersible tablet. The later Videx EC product used delayed-release capsules to reduce the need for direct exposure to alkaline excipients and to improve administration convenience. The FDA label identifies didanosine as a prescription antiretroviral and includes warnings for pancreatitis, peripheral neuropathy, lactic acidosis, hepatotoxicity, and retinal changes [1, 2].

Product attribute	Didanosine position
Active ingredient	Didanosine, 2',3'-dideoxyinosine
Therapeutic class	Nucleoside reverse-transcriptase inhibitor
Original innovator	Bristol-Myers Squibb
Initial FDA approval	1991
Principal dosage forms	Buffered chewable/dispersible tablets; delayed-release capsules
Pediatric relevance	Important historical use, particularly where liquid dosing was needed
Current U.S. commercial status	Legacy/discontinued or limited-market product status, depending on presentation and database
Core patent position	Original composition and formulation rights are expired
Current commercial barrier	Low market demand, complex excipient requirements, safety monitoring, and competition from newer antiretrovirals

What excipients were used in didanosine formulations?

Didanosine has limited stability in acidic conditions. Legacy formulations therefore used alkaline buffering systems to raise local pH and protect the active ingredient in the dosage form and gastrointestinal tract.

Typical excipient categories included:

• Antacid or buffering agents, including magnesium- and calcium-containing compounds
• Alkalinizing salts
• Compressibility and binding agents
• Disintegrants
• Sweeteners and flavors for chewable or dispersible tablets
• Lubricants and glidants
• Capsule-shell materials
• Suspending and viscosity-control agents for liquid formulations

The precise composition varied by product and strength. Formulation work should rely on the applicable FDA label, approved product records, and any available regulatory chemistry documentation rather than assuming that a historical generic formula remains suitable.

Why buffering is central to didanosine formulation

Didanosine’s acid sensitivity creates four formulation constraints:

1. The dosage form must maintain an alkaline microenvironment.
2. Acidic excipients, acidic flavors, and low-pH liquid vehicles can reduce stability.
3. Food can affect exposure and administration instructions.
4. Mineral buffering agents can create dose bulk, poor mouthfeel, and manufacturing variability.

The formulation objective is therefore not simply to maximize dissolution. It is to control pH, moisture, compatibility, and release while preserving acceptable dose size and patient administration.

What excipient strategy is most suitable for a new didanosine product?

A commercial formulation program should begin with a buffered solid dosage form rather than an aqueous liquid. Solid-state protection generally reduces hydrolysis risk, limits microbial concerns, and simplifies distribution.

Recommended platform strategy

Formulation platform	Technical value	Commercial assessment
Buffered chewable tablet	Familiar technology; suitable for patients unable to swallow capsules	Potentially useful for pediatric or institutional markets, but taste and tablet bulk are difficult
Buffered dispersible tablet	Supports administration in water and flexible dosing	Strongest legacy-compatible option if palatability and dispersion are improved
Delayed-release capsule	Reduces direct reliance on highly alkaline tablet excipients	More convenient, but less suitable for young children and may require specialized release testing
Multiparticulate sachet	Enables flexible dosing and potential pediatric administration	Attractive for low-volume tenders if stability and dose uniformity are demonstrated
Oral suspension	Supports pediatric dosing	High risk because of acid sensitivity, hydrolysis, microbial control, and limited market size
Enteric-coated tablet	Can control release location	Less attractive than a buffered system unless the product has a clear pharmacokinetic or tolerability advantage
Fixed-dose combination	Could improve adherence and reduce pill burden	Commercially difficult because current HIV regimens have largely replaced didanosine

Preferred excipient architecture

A rational development sequence would assess:

• A dry alkaline buffer system with controlled particle size
• Low-moisture excipients
• A neutral or alkaline flavor system
• A low-hygroscopic binder
• A rapidly dispersible matrix for pediatric administration
• Protective packaging with desiccant where justified
• Compatibility with water, milk substitutes, and commonly used administration vehicles

Calcium carbonate, magnesium hydroxide, magnesium carbonate, and related alkaline materials may be technically relevant, but their use requires control of elemental impurities, particle-size distribution, sedimentation, mouthfeel, and dose uniformity. The excipient selection should also account for renal impairment and the possibility of interactions with other orally administered medicines.

A new formulation should avoid acidic organic acids, acidic fruit flavors, and excipients that materially increase water activity. Sweetener selection matters because high sugar content can reduce suitability for pediatric patients, dental-risk populations, and long-term administration.

What formulations are protected by didanosine patents?

The historical patent estate covered the active compound, pharmaceutical compositions, buffered dosage forms, and related uses. Those rights are now old enough that the principal composition and formulation patents have expired or reached the end of their enforceable terms.

The commercial implication is direct:

• A generic manufacturer is unlikely to face a meaningful composition-of-matter barrier.
• A new buffered tablet can generally be developed without relying on a license to Bristol-Myers Squibb.
• A novel excipient system, particle engineering approach, release profile, or packaging configuration could support new patent filings.
• Any new patents would protect only the specific improvement, not didanosine itself.

A freedom-to-operate review would still need to screen later patents covering particular combinations, manufacturing processes, coating systems, and delivery technologies. The absence of active core exclusivity does not eliminate the possibility of narrower third-party rights.

When did didanosine lose exclusivity?

Didanosine lost meaningful market exclusivity years ago. Its original U.S. approval occurred in 1991, and its core patents are expired. Any pediatric exclusivity, orphan-style protection, or regulatory exclusivity associated with the historical approvals is no longer commercially relevant.

Exclusivity category	Current position
Composition patent	Expired
Original formulation patents	Expired or commercially immaterial
FDA new-drug exclusivity	Expired
Pediatric exclusivity	Expired
Orphan exclusivity	Not a current barrier
Orange Book patent protection	No meaningful active core protection identified in current public records
Biosimilar exclusivity	Not applicable

What is the Orange Book status of didanosine?

Didanosine is a small-molecule drug, so the applicable FDA pathway is abbreviated new drug approval, not biosimilar approval. Historical Videx and Videx EC listings may remain visible in FDA databases even where the product is discontinued or no longer actively marketed.

The key regulatory distinction is between:

• A product listed as approved but not currently marketed
• A discontinued product
• A product with no active commercial sponsor
• A generic product that has an approved ANDA but limited or no current supply

Orange Book records should be checked for the exact dosage form and strength. A listing alone does not establish active commercial availability or a surviving patent barrier [3].

Are there Paragraph IV challenges to didanosine?

Paragraph IV litigation is unlikely to be commercially significant for didanosine today. The principal patents covering the innovator product expired long ago, and the market has not generated the type of current, high-value patent dispute associated with major branded medicines.

For a new generic or reformulated product, the main regulatory pathway would normally be an ANDA referencing the relevant listed drug, subject to product-specific bioequivalence and labeling requirements. If the reference product is discontinued or difficult to source, regulatory strategy may require careful assessment of reference-product availability and FDA eligibility.

The commercial risk is therefore less likely to come from patent litigation than from:

• Difficulty obtaining a commercially useful reference product
• Low prescription volume
• Limited payer demand
• Supply-chain costs
• Formulation-specific bioequivalence requirements
• Lack of inclusion in modern treatment guidelines

What is the biosimilar risk for didanosine?

Biosimilar risk is not applicable. Didanosine is a chemically synthesized small molecule, not a biologic. Competitive entry would occur through generic-drug pathways, including ANDA approval or, depending on the product and regulatory facts, another small-molecule application route.

The relevant competition is from newer antiretroviral regimens, not from biosimilars.

Which companies are challenging or competing with didanosine?

The commercial competitive set has shifted away from other didanosine manufacturers. Current HIV treatment is dominated by integrase-strand-transfer inhibitors and fixed-dose combinations containing agents such as dolutegravir, bictegravir, tenofovir, emtricitabine, and lamivudine.

Historically, didanosine competed with zidovudine, stavudine, lamivudine, zalcitabine, and protease-inhibitor-based regimens. Current guidelines generally favor more effective and better-tolerated regimens over didanosine because of its toxicity profile and dosing limitations [4].

Competitive category	Impact on didanosine
Modern integrase-inhibitor combinations	High substitution risk
Older generic NRTIs	Direct historical competition
Pediatric liquid antiretrovirals	Limited niche overlap
Long-acting injectable HIV therapy	Different administration model, but strong adherence competition
Salvage-therapy products	Potential residual niche, subject to specialist demand
Global tender products	Possible opportunity where price and availability dominate

What commercial opportunities remain for didanosine?

The strongest opportunities are niche opportunities rather than mass-market launches.

Pediatric and dispersible dosage forms

A low-volume dispersible tablet or sachet could address settings where swallowing capsules is difficult. The product would need:

• Dose flexibility
• Rapid dispersion
• Acceptable taste
• Stable storage in hot and humid climates
• Clear instructions for administration with water
• Minimal use of refrigerated distribution

This segment is constrained by the decline in didanosine use and the availability of preferred pediatric antiretrovirals.

Resource-limited markets

A manufacturer could evaluate didanosine for countries where historical treatment protocols remain in use or where procurement agencies require low-cost reserve products. Success would depend on registration, tender access, WHO or national guideline alignment, and reliable supply.

The product would need a cost structure capable of absorbing:

• Small production batches
• Stability studies in climatic zones III and IV
• Multilingual labeling
• Pharmacovigilance
• Regulatory maintenance across multiple jurisdictions

Clinical research and specialty supply

Didanosine may retain value in research settings involving:

• Historical antiretroviral comparisons
• Drug-interaction studies
• HIV pharmacology research
• Resistance studies
• Reference-material supply

These are unlikely to support a large commercial manufacturing program but may justify contract manufacturing or controlled specialty distribution.

Reformulation licensing

A formulation developer could seek rights around a specific improvement, such as:

• A low-bulk alkaline buffer
• A taste-masked dispersible product
• A moisture-resistant multiparticulate system
• A stable room-temperature pediatric suspension
• A combination product for a defined legacy market

A licensing transaction would make commercial sense only if it includes a committed buyer, tender channel, or strategic distributor. A formulation patent without market access would have limited value.

How strong is the didanosine patent estate?

The historical estate is weak from a current enforcement perspective but potentially useful as prior art for formulation design.

Patent-estate factor	Assessment
Core molecule protection	Expired
Historical branded formulation protection	Expired
Current blocking rights	Low based on public historical status
Opportunity for improvement patents	Moderate, if claims show unexpected stability, taste, release, or bioavailability benefits
Litigation exposure	Low
Freedom-to-operate complexity	Moderate for specialized delivery systems
Value of trade secrets	Moderate for process control and excipient handling

New patent claims would need to focus on measurable product differences. Broad claims to "a didanosine composition" would face substantial novelty and obviousness pressure. Stronger claim themes would include specific excipient ratios, moisture thresholds, particle-size limits, pH profiles, release characteristics, or demonstrated stability under accelerated conditions.

What manufacturing and intellectual-property barriers exist?

Manufacturing complexity is manageable but not trivial. The largest risks are associated with alkaline excipients and product uniformity.

Critical controls include:

• Active and excipient particle-size distribution
• Blend uniformity
• Local pH
• Moisture content and water activity
• Tablet hardness and friability
• Dispersion time
• Taste-masking performance
• Packaging moisture ingress
• Stability of the finished product under high temperature and humidity
• Compatibility with co-administered medicines

A buffered product may have a larger tablet mass than a conventional immediate-release tablet. That can reduce patient acceptance and increase shipping cost. A delayed-release capsule can improve administration but may create more demanding dissolution and coating controls.

How does didanosine compare with modern HIV medicines?

Attribute	Didanosine	Modern preferred antiretroviral regimen
Dosing convenience	Historically limited by fasting and formulation instructions	Often once daily with fewer administration restrictions
Toxicity profile	Pancreatitis, neuropathy, mitochondrial toxicity, lactic acidosis concerns	Generally more favorable, depending on regimen
Formulation opportunity	Buffered dispersible or delayed-release products	Fixed-dose and long-acting platforms
Patent position	Core rights expired	Many products retain active patents or market exclusivity
Commercial demand	Low and declining	High for guideline-preferred regimens
Generic opportunity	Niche	Stronger where high-volume products lose exclusivity
Development rationale	Access, legacy supply, specialty use	Broad treatment-market expansion

What generic launch scenarios exist for didanosine?

Three launch scenarios are plausible:

1. Low-cost legacy generic: A conventional buffered tablet or capsule for residual markets. This has the lowest development cost but also the weakest demand outlook.
2. Pediatric dispersible product: A differentiated product targeting flexible dosing and improved palatability. This offers more defensible commercial positioning but requires formulation development and pediatric usability work.
3. Specialty or tender product: A controlled-volume product supplied through government procurement, research institutions, or specialist distributors. This minimizes commercial infrastructure but depends on contracted demand.

A broad retail launch is difficult to justify because modern antiretroviral regimens have displaced didanosine in most treatment settings.

Key Takeaways

• Didanosine is an off-patent, small-molecule antiretroviral with no biosimilar pathway.
• Its principal formulation challenge is acid sensitivity, making alkaline buffering and moisture control central to product design.
• Buffered chewable, dispersible, and multiparticulate products offer the clearest technical opportunities.
• Aqueous suspensions are possible but carry higher stability, microbiological, and commercial risks.
• Core composition and historical formulation patents are expired; new protection would need to cover a defined formulation improvement.
• Paragraph IV litigation and Orange Book patent risk are likely low compared with manufacturing, demand, and regulatory risks.
• The strongest remaining commercial opportunities are pediatric dispersible products, resource-limited-market supply, specialty distribution, and clinical research.
• A new product requires a committed procurement or distribution channel because guideline-preferred HIV regimens have largely replaced didanosine.

FAQs

Is didanosine still used in HIV treatment?

Use is limited. Modern HIV guidelines generally favor newer, better-tolerated antiretroviral regimens, while didanosine may remain relevant in isolated legacy, research, or specialist settings.

Can didanosine be formulated as a liquid?

Yes, but an oral liquid presents greater hydrolysis, microbial stability, taste, and packaging challenges than a dry buffered dosage form.

Why did didanosine tablets contain antacid ingredients?

The alkaline excipients helped protect acid-sensitive didanosine and supported product stability and performance after oral administration.

Can a company patent a new didanosine formulation?

Yes, if the formulation contains a novel and non-obvious technical improvement, such as improved stability, taste, dispersion, release, or moisture resistance. The active ingredient itself is not a viable source of new composition-of-matter protection.

Is didanosine suitable for a fixed-dose combination?

Technically possible, but commercially difficult. Compatibility, dose scheduling, toxicity, and the availability of preferred modern combinations substantially limit the opportunity.

References

1. U.S. Food and Drug Administration. (1991). Videx (didanosine) prescribing information.
2. U.S. Food and Drug Administration. (2000). Videx EC (didanosine) delayed-release capsules prescribing information.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Department of Health and Human Services. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. ClinicalInfo.HIV.gov.